![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Background
An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of18F-FDG-PET/CT for survival following first-line treatment in PTCL patients.
Research design and methods
Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.
Results
Fifty patients were evaluated with18F-FDG-PET/CT following first-line therapy: 58% were18F-FDG-PET/CT-negative and 42% were18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of18F-FDG-PET/CT-negative patients and in 80.9% of18F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for18F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60–31.31; p = 0.001).
Conclusions
18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.
Declaration of interest
R Cordoba: Speakers bureau, consulting/advisory role for Takeda, and travel and accommodation by Takeda. J Sánchez-García: Research funding by Janssen and Roche. Speakers bureau for Abbvie, Janssen, BSM, Roche, and Takeda. E Domingo-Domenech: Consulting/advisory role for Takeda. Research funding by Bristol-Myers Squibb, Seattle Genetics, Inc., and Takeda. Travel, accommodation and expenses by Bristol-Myers Squibb, Takeda, Roche, and Janssen. J López Jiménez: Research funding by Abbvie, Janssen, MSD, Roche and Takeda. Speakers bureau for Abbvie, Janssen, MSD, Roche, and Takeda. C Carpio: Speakers bureau for Regeneron, Takeda, Celgene, Novartis, and Roche. A Bendaña: Speakers bureau for Roche. S González de Villambrosia: Speakers bureau for Janssen and Roche. G Rodríguez: Consulting/advisory for Roche, Janssen, Celgene, and Takeda. A Naves: Employee of Takeda Farmacéutica España S.A. L Baeza: Employee of Takeda Farmacéutica España. S.A. AM Martín García-Sancho: Research funding by Janssen, Celgene. Consulting/advisory for Roche, Servier, Celgene/BMS, Clinigen, Eusa Pharma, Gilead, Kyowa Kirin, Novartis, and Morphosys. Speakers bureau for Roche, Celgene, Janssen, Servier, Gilead, and Takeda.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contributions
R Cordoba: designed the research, performed the tests and statistics, and reviewed the manuscript. J Sánchez-García, E Domingo-Domenech, J López Jiménez, A Martínez Pozo, C Carpio, A Bendaña, AJ González, S González de Villambrosia, J Gómez Codina, B Navarro, G Rodríguez, and A Martín García-Sancho reviewed the medical records to identify patients diagnosed with PTCL, recorded the data used in the study, and reviewed the manuscript. A Naves and L Baeza revised the article. All of the authors approved the final version of the manuscript for submission.
Acknowledgments
The authors wish to thank McCann Health and Fernando Sánchez Barbero, PhD, for the support on the preparation of this manuscript.
Data availability statement
All data generated or analyzed during this study are included in this published article.